AU2012320597C1 - oxMIF as a diagnostic marker - Google Patents

oxMIF as a diagnostic marker Download PDF

Info

Publication number
AU2012320597C1
AU2012320597C1 AU2012320597A AU2012320597A AU2012320597C1 AU 2012320597 C1 AU2012320597 C1 AU 2012320597C1 AU 2012320597 A AU2012320597 A AU 2012320597A AU 2012320597 A AU2012320597 A AU 2012320597A AU 2012320597 C1 AU2012320597 C1 AU 2012320597C1
Authority
AU
Australia
Prior art keywords
mif
oxmif
antibody
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012320597A
Other languages
English (en)
Other versions
AU2012320597A1 (en
AU2012320597B2 (en
Inventor
Patrice DOUILLARD
Randolf J. Kerschbaumer
Friedrich Scheiflinger
Michael Thiele
Dirk Voelkel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxalta GmbH
Baxalta Inc
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Publication of AU2012320597A1 publication Critical patent/AU2012320597A1/en
Assigned to BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SA reassignment BAXTER INTERNATIONAL INC. Amend patent request/document other than specification (104) Assignors: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
Application granted granted Critical
Publication of AU2012320597B2 publication Critical patent/AU2012320597B2/en
Publication of AU2012320597C1 publication Critical patent/AU2012320597C1/en
Assigned to Baxalta GmbH, BAXALTA INCORPORATED reassignment Baxalta GmbH Request for Assignment Assignors: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
AU2012320597A 2011-10-07 2012-10-04 oxMIF as a diagnostic marker Ceased AU2012320597C1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161545042P 2011-10-07 2011-10-07
US61/545,042 2011-10-07
US201261624943P 2012-04-16 2012-04-16
US61/624,943 2012-04-16
US201261668841P 2012-07-06 2012-07-06
US61/668,841 2012-07-06
PCT/EP2012/069598 WO2013050453A1 (en) 2011-10-07 2012-10-04 Oxmif as a diagnostic marker

Publications (3)

Publication Number Publication Date
AU2012320597A1 AU2012320597A1 (en) 2013-05-09
AU2012320597B2 AU2012320597B2 (en) 2015-05-21
AU2012320597C1 true AU2012320597C1 (en) 2015-10-15

Family

ID=46980957

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012320597A Ceased AU2012320597C1 (en) 2011-10-07 2012-10-04 oxMIF as a diagnostic marker

Country Status (8)

Country Link
US (1) US9958456B2 (https=)
EP (1) EP2748613B1 (https=)
JP (1) JP2014530360A (https=)
AR (1) AR088244A1 (https=)
AU (1) AU2012320597C1 (https=)
HK (1) HK1198591A1 (https=)
TW (1) TW201321408A (https=)
WO (1) WO2013050453A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530360A (ja) 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
EP2872897B1 (en) * 2012-07-10 2017-10-18 Baxalta GmbH Anti-mif immunohistochemistry
US9536304B2 (en) * 2013-08-30 2017-01-03 Dairy Quality Inc. Determining pathogens based on an image of somatic cells in a fluid sample
EP3052943B1 (en) * 2013-10-04 2019-11-20 Cell Ideas Pty Ltd. Biomarkers for cell therapy
WO2015106973A2 (en) * 2014-01-03 2015-07-23 Baxter Healthcare S.A. Anti-mif immunohistochemistry
WO2016026956A1 (en) * 2014-08-22 2016-02-25 Baxalta GmbH Detection of cho-mif contaminations
EP3802595A1 (en) * 2018-06-07 2021-04-14 OncoOne Research & Development GmbH Anti-oxmif/anti-cd3 antibody for cancer treatment
JP2023504620A (ja) * 2019-12-06 2023-02-06 オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 抗ｏｘＭＩＦ／抗ＣＤ３二重特異性抗体構築物
AU2022218320A1 (en) * 2021-02-03 2023-07-27 Oncoone Research & Development Gmbh ANTI-oxMIF RADIOIMMUNOCONJUGATE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064749A2 (en) * 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
WO2009087920A1 (en) * 2008-01-08 2009-07-16 Nec Corporation Method for optimizing the triggering of the transmission of buffer status reporting (bsr) information

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299814A (en) 1979-05-25 1981-11-10 Monsanto Company Radioimmunoassay of MIF
JPH0672158B2 (ja) * 1984-05-24 1994-09-14 チバ−ガイギ− アクチエンゲゼルシヤフト 精製されたヒトマクロファージ遊走阻止因子
US4946674A (en) 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
US4708937A (en) 1984-10-15 1987-11-24 Brigham & Women's Hospital Purified migration inhibitory factor also having colony stimulating factor activity
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ES2052602T3 (es) 1986-10-03 1994-07-16 Ciba Geigy Ag Nuevos peptidos afines a las linfocinas.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0463037A1 (en) 1989-03-17 1992-01-02 Genetics Institute, Inc. Human macrophage migration inhibitory factor
US5785054A (en) 1989-06-06 1998-07-28 Kelly; Patrick D. Genital lubricant with zinc salt, labelled as anti-viral agent
GB8915414D0 (en) 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
CA2044590A1 (en) 1989-11-13 1991-05-14 Marc D. Better Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5227459A (en) 1990-05-18 1993-07-13 Yale University Synthetic melanin
US5786168A (en) 1990-06-04 1998-07-28 Kirin Beer Kabushiki Kaisha Method for recombinant production of antigen non-specific glycosylation inhibiting factor (GIF)
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US6774227B1 (en) 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
DE69435303D1 (de) 1993-05-17 2010-09-02 Cytokine Pharmasciences Inc Er behandlung von krankheiten bei denen eine cytok
US6645493B1 (en) 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
US5559028A (en) 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
EP0770086A4 (en) 1994-05-16 1998-07-15 Human Genome Sciences Inc MACROPHAGE MIGRATION INHIBITING FACTOR-3
US5747023A (en) 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
SI9400363A (en) 1994-09-19 1996-08-31 Mozetic Francky Bojana Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein
WO1996015242A2 (en) 1994-11-16 1996-05-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor
JPH0977799A (ja) 1995-09-13 1997-03-25 Sapporo Immuno Diagnostic Lab:Kk ヒト−マクロファージ遊走阻止因子（ヒト−ｍｉｆ）に対するモノクローナル抗体および該抗体を産生するハイブリドーマ
AU1087797A (en) 1996-01-03 1997-08-01 Australian National University, The Clip analogues and autoimmune disease
US6420188B1 (en) 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US5726020A (en) 1996-06-11 1998-03-10 University Of Massachusetts Inhibition of II synthesis
US6297253B1 (en) 1996-10-15 2001-10-02 The Picower Institute For Medical Research Compounds and methods of use to treat infectious diseases
AU6336398A (en) 1997-02-24 1998-09-09 Johns Hopkins University, The Immunomodulatory polypeptides derived from the invariant chain of mhc class ii
ES2248898T3 (es) 1997-05-02 2006-03-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Inmunotoxinas que comprenden una proteina onc dirigida contra celulas malignas.
CA2205680A1 (en) 1997-05-16 1998-11-16 The University Of Western Ontario Clip immunomodulatory peptide
US6011005A (en) 1997-09-18 2000-01-04 The Picower Institute For Medical Research Prevention of pregnancy miscarriages
PT1028738E (pt) 1997-11-05 2003-08-29 Univ Southern California Utilizacao de citoquinas e mitogenios para inibir respostas imunitarias patologicas
HU229520B1 (en) 1999-02-12 2014-01-28 Scripps Research Inst Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
WO2001032606A1 (en) 1999-10-29 2001-05-10 The Picower Institute For Medical Research Compounds having mif antagonist activity
US6268151B1 (en) 2000-01-20 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of macrophage migration inhibitory factor expression
WO2002079517A1 (en) 2001-03-29 2002-10-10 Cytokine Pharmasciences, Inc. Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
US7205107B2 (en) 2001-12-21 2007-04-17 Cytokine Pharmasciences, Inc. Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease
US20050202010A1 (en) 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
US8883160B2 (en) 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
CN101374546B (zh) 2005-12-16 2016-03-23 Ibc医药公司 基于免疫球蛋白的多价生物活性装配体
CN100457895C (zh) 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
KR20160105943A (ko) 2008-01-04 2016-09-07 백스터 인터내셔널 인코포레이티드 항 ｍｉｆ 항체
WO2011090492A1 (en) 2010-01-19 2011-07-28 Immunomedics, Inc. Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
WO2013050457A1 (en) 2011-10-07 2013-04-11 Baxter Healthcare S.A. Characterization of cho-mif gene and protein, and use thereof
JP2014530360A (ja) 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064749A2 (en) * 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
WO2009087920A1 (en) * 2008-01-08 2009-07-16 Nec Corporation Method for optimizing the triggering of the transmission of buffer status reporting (bsr) information

Also Published As

Publication number Publication date
HK1198591A1 (en) 2015-04-30
AR088244A1 (es) 2014-05-21
EP2748613A1 (en) 2014-07-02
US20140248638A1 (en) 2014-09-04
WO2013050453A1 (en) 2013-04-11
WO2013050453A4 (en) 2013-06-06
JP2014530360A (ja) 2014-11-17
AU2012320597A1 (en) 2013-05-09
TW201321408A (zh) 2013-06-01
AU2012320597B2 (en) 2015-05-21
US9958456B2 (en) 2018-05-01
EP2748613B1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
AU2012320597C1 (en) oxMIF as a diagnostic marker
TW202221039A (zh) 犬及貓抑瘤素Ｍ受體β之抗體及其用途
US20240018220A1 (en) Methods of treating patients having complement disorders using anti-c5 antibodies
US20170210794A1 (en) Characterization of cho-mif gene and protein, and use thereof
CN119390843B (zh) 抗tl1a抗体及其制备方法和应用
US10613100B2 (en) Anti-MIF immunohistochemistry
JP6892180B2 (ja) 活性型インターロイキン−１８タンパク質のネオエピトープを認識する抗体、及びその応用
US11402388B2 (en) Anti-MIF immunohistochemistry
WO2015071416A2 (en) Mif as therapeutic target
CN104884955B (zh) 抗‑mif抗体的细胞迁移测定方法
US20200207840A1 (en) Detection of cho-mif contaminations
MX2015000447A (es) Imunohistoquimica anti-mif.
JPWO2019194217A1 (ja) 検出感度の高いインターロイキン−１８タンパク質に対する抗体及びその応用

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 JUN 2015 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 JUN

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BAXALTA GMBH; BAXALTA INCORPORATED

Free format text: FORMER OWNER WAS: BAXTER HEALTHCARE SA; BAXTER INTERNATIONAL INC.